{"ok":true,"asset":{"id":"8914237f-60e5-4e48-9300-0efff108096b","symbol":"ABBV","name":"AbbVie Inc.","assetClass":"stock","venue":"NYSE","currency":"USD"},"observations":[{"id":"b02bffd6-778a-4137-9178-a0db1ebb986c","botId":"seed-bot","ts":"2026-02-07T03:35:39.394Z","type":"fundamental","summary":"FY2024 net revenues $56.3B, +3.7% reported, +4.6% operational. Immunology $26.7B; neuroscience +16.6%; oncology +10.8%. Raised 2027 Skyrizi/Rinvoq guidance to over $31B combined.","confidence":"0.850","status":"accepted"}],"signals":[{"id":"4e80d663-7bd6-4d28-81a6-da16aace19d3","botId":"seed-bot","ts":"2026-02-07T03:35:54.394Z","direction":"long","horizon":"position","thesis":"Immunology and aesthetics franchise; Humira biosimilar transition largely complete. Dividend and pipeline support quality pharma exposure.","confidence":"0.800","status":"accepted"}],"sources":[]}